StockData
Tempest Therapeutics, Inc. logo

Tempest Therapeutics, Inc. (TPST) stock

TPSTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 13, 2026Score 4/30
$0.33−0.01 (-4.24%)

Close on Nov 17, 2026Market cap $4.85MP/E –Yield –

Tempest Therapeutics operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Tempest Therapeutics's operating income for the twelve months ending Jun 30, 2026 was -$40.64M. For fiscal 2025 it was -$26.58M. The highest annual figure on record is -$13.53M in fiscal 2012.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$26.58M–
FY2024Dec 31, 2024-$42.03M–
FY2023Dec 31, 2023-$29.16M–
FY2022Dec 31, 2022-$34.64M–
FY2021Dec 31, 2021-$26.99M–
FY2020Dec 31, 2020-$19.30M–
FY2019Dec 31, 2019-$45.40M–
FY2018Dec 31, 2018-$26.87M–
FY2017Dec 31, 2017-$84.33M–
FY2016Dec 31, 2016-$81.01M–
FY2015Dec 31, 2015-$72.00M–
FY2014Dec 31, 2014-$47.93M–
FY2013Dec 31, 2013-$29.13M–
FY2012Dec 31, 2012-$13.53M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$5.25M–
Q1 FY2026Mar 31, 2026-$27.72M–
Q4 FY2025Dec 31, 2025-$4.08M–
Q3 FY2025Sep 30, 2025-$3.60M–
Q2 FY2025Jun 30, 2025-$7.97M–
Q1 FY2025Mar 31, 2025-$10.94M–
Q4 FY2024Dec 31, 2024-$13.92M–
Q3 FY2024Sep 30, 2024-$10.55M–
Q2 FY2024Jun 30, 2024-$9.58M–
Q1 FY2024Mar 31, 2024-$7.97M–
Q4 FY2023Dec 31, 2023-$7.51M–
Q3 FY2023Sep 30, 2023-$6.59M–
Q2 FY2023Jun 30, 2023-$7.47M–
Q1 FY2023Mar 31, 2023-$7.58M–
Q4 FY2022Dec 31, 2022-$8.93M–
Q3 FY2022Sep 30, 2022-$8.77M–
Q2 FY2022Jun 30, 2022-$8.77M–
Q1 FY2022Mar 31, 2022-$8.16M–
Q4 FY2021Dec 31, 2021-$7.34M–
Q3 FY2021Sep 30, 2021-$7.74M-242.4%
Q2 FY2021Jun 30, 2021-$6.79M–
Q1 FY2021Mar 31, 2021-$5.13M–
Q4 FY2020Dec 31, 2020-$34.27M–
Q3 FY2020Sep 30, 2020$5.43M–
Q2 FY2020Jun 30, 2020-$5.24M–
Q1 FY2020Mar 31, 2020-$12.14M–
Q4 FY2019Dec 31, 2019-$12.83M–
Q3 FY2019Sep 30, 2019-$11.75M–
Q2 FY2019Jun 30, 2019-$10.16M–
Q1 FY2019Mar 31, 2019-$10.66M–
Q4 FY2018Dec 31, 2018-$9.69M–
Q3 FY2018Sep 30, 2018-$7.81M–
Q2 FY2018Jun 30, 2018-$4.99M–
Q1 FY2018Mar 31, 2018-$4.39M–
Q4 FY2017Dec 31, 2017-$42.40M–
Q3 FY2017Sep 30, 2017-$9.41M–
Q2 FY2017Jun 30, 2017-$17.93M–
Q1 FY2017Mar 31, 2017-$14.59M–
Q4 FY2016Dec 31, 2016-$22.37M–
Q3 FY2016Sep 30, 2016-$18.96M–

More Tempest Therapeutics figures

See a number that looks wrong?